Literature DB >> 12438344

Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice.

Farhat Afrin1, Ravindran Rajesh, Khairul Anam, Meenakshisundram Gopinath, Swati Pal, Nahid Ali.   

Abstract

Leishmania donovani promastigote membrane antigens (LAg) encapsulated in positively charged liposomes have been found to induce very significant levels of protection against experimental visceral leishmaniasis. The protectively immunized animals exhibited profound delayed-type hypersensitivity and antibody responses. The extent of protection induced by the same antigens, however, varied depending on the charge of the vesicles, with maximum induction by positively charged liposomes, followed by neutral liposomes and last negatively charged liposomes. Characterization of LAg and LAg entrapped in liposomes of different charges by Western blot analysis revealed the immunodominance of gp63 in all three vaccine preparations. The strong reactivity of antigens in a restricted antigen profile that included, in addition to gp63, 72-, 52-, 48-, 45-, 39-, and 20-kDa components in neutral and positively charged liposomes contrasted with the reactivity of a greater number of LAg components in negatively charged liposomes. Resistance to visceral leishmaniasis appears to depend on the immunity induced by gp63 and a few select antigens in association with the right liposomes. A striking similarity between the immunogenic profile of partially purified soluble antigens and that of LAg in neutral and positively charged liposomes suggests the potentiality of these antigens in future vaccine studies of L. donovani.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12438344      PMCID: PMC133102          DOI: 10.1128/IAI.70.12.6697-6706.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  62 in total

1.  Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.

Authors:  L P Kahl; C A Scott; R Lelchuk; G Gregoriadis; F Y Liew
Journal:  J Immunol       Date:  1989-06-15       Impact factor: 5.422

2.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

Review 3.  T-cell and cytokine responses in leishmaniasis.

Authors:  S G Reed; P Scott
Journal:  Curr Opin Immunol       Date:  1993-08       Impact factor: 7.486

4.  Immunization of mice against Leishmania donovani by subcutaneous injections of dead promastigotes.

Authors:  T W Holbrook; J A Cook
Journal:  Am J Trop Med Hyg       Date:  1983-01       Impact factor: 2.345

5.  Membrane glycoprotein M-2 protects against Leishmania amazonensis infection.

Authors:  J Champsi; D McMahon-Pratt
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

6.  Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis.

Authors:  C L Jaffe; N Rachamim; R Sarfstein
Journal:  J Immunol       Date:  1990-01-15       Impact factor: 5.422

7.  Prophylactic immunization against experimental leishmaniasis. III. Protection against fatal Leishmania tropica infection induced by irradiated promastigotes involves Lyt-1+2- T cells that do not mediate cutaneous DTH.

Authors:  F Y Liew; J G Howard; C Hale
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

8.  Immunoprotective Leishmania major synthetic T cell epitopes.

Authors:  A Jardim; J Alexander; H S Teh; D Ou; R W Olafson
Journal:  J Exp Med       Date:  1990-08-01       Impact factor: 14.307

9.  Surface antigens of Leishmania donovani promastigotes.

Authors:  D A Lepay; N Nogueira; Z Cohn
Journal:  J Exp Med       Date:  1983-05-01       Impact factor: 14.307

10.  Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets.

Authors:  F P Heinzel; M D Sadick; B J Holaday; R L Coffman; R M Locksley
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more
  35 in total

1.  In vitro responses of human peripheral blood mononuclear cells to whole-cell, particulate and soluble extracts of Leishmania promastigotes.

Authors:  E Telino; P M De Luca; D C S Matos; R B Azeredo-Coutinho; M N Meirelles; F Conceição-Silva; A Schubach; S C F Mendonça
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

Review 2.  Proteoliposomes in nanobiotechnology.

Authors:  P Ciancaglini; A M S Simão; M Bolean; J L Millán; C F Rigos; J S Yoneda; M C Colhone; R G Stabeli
Journal:  Biophys Rev       Date:  2012-01-18

3.  Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis.

Authors:  Anil Kumar Jaiswal; Prashant Khare; Sumit Joshi; Pramod Kumar Kushawaha; Shyam Sundar; Anuradha Dube
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

4.  Negatively charged liposomes show potent adjuvant activity when simply admixed with protein antigens.

Authors:  Nijaporn Yanasarn; Brian R Sloat; Zhengrong Cui
Journal:  Mol Pharm       Date:  2011-06-07       Impact factor: 4.939

5.  Combination therapy with paromomycin-associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation.

Authors:  Antara Banerjee; Manjarika De; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

6.  Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis.

Authors:  Vahid Heravi Shargh; Mahmoud Reza Jaafari; Ali Khamesipour; Seyed Amir Jalali; Hengameh Firouzmand; Azam Abbasi; Ali Badiee
Journal:  Parasitol Res       Date:  2012-01-06       Impact factor: 2.289

7.  Characterization of immunoglobulin G and its subclass response to Indian kala-azar infection before and after chemotherapy.

Authors:  Rajesh Ravindran; Khairul Anam; Bibhas C Bairagi; Bibhuti Saha; Netai Pramanik; Subhasis K Guha; Rama P Goswami; Dwijadas Banerjee; Nahid Ali
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

8.  gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.

Authors:  Swati Bhowmick; Rajesh Ravindran; Nahid Ali
Journal:  Infect Immun       Date:  2008-01-14       Impact factor: 3.441

9.  Evaluation of Cysteine Protease C of Leishmania donovani in Comparison with Glycoprotein 63 and Elongation Factor 1α for Diagnosis of Human Visceral Leishmaniasis and for Posttreatment Follow-Up Response.

Authors:  Nicky Didwania; Sarfaraz Ahmad Ejazi; Rudra Chhajer; Abdus Sabur; Saumyabrata Mazumder; Mohd Kamran; Raunak Kar; Krishna Pandey; Vidya Nand Ravi Das; Pradeep Das; Mehebubar Rahaman; Rama Prosad Goswami; Nahid Ali
Journal:  J Clin Microbiol       Date:  2020-10-21       Impact factor: 5.948

10.  Immunogenicity and efficacy of single antigen Gp63, polytope and polytopeHSP70 DNA vaccines against visceral Leishmaniasis in experimental mouse model.

Authors:  Rakhee Sachdeva; Akhil C Banerjea; Nancy Malla; Mohan Lal Dubey
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.